Changes in urinary monoamine metabolites with antipsychotic treatment in schizophrenia

Manu Arora, Daya Ram, Samir Kumar Praharaj

Research output: Contribution to journalArticle

Abstract

Objective: Monoamine neurotransmitters have been considered important mediators of schizophrenia pathology and antipsychotic drug action. This study examines the level of monoamine metabolites, homovanillic acid (HVA), 5-hydroxy indole acetic acid (5-HIAA), and vanillylmandelic acid (VMA), monoamine metabolites of major neurotransmitters dopamine, serotonin and norepinephrine, respectively in urine of patients with schizophrenia as compared to normal controls and the change in monoamine metabolites with antipsychotic treatment. Methods: Thirty-four drug-free patients with schizophrenia diagnosed with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria and 15 normal controls were taken for the study. Patients were assessed for psychopathology using positive and negative syndrome scale (PANSS) scale at baseline and 4 weeks after the treatment. Urinary monoamine metabolites (HVA, 5-HIAA, and VMA) were measured before and after 4 weeks of treatment using high-performance liquid chromatography. Results: There was a trend toward higher levels of HVA and VMA in the patients as compared to controls. There was a trend toward reduction in 5-HIAA levels with treatment in patients with schizophrenia. No correlation was found between the levels of monoamine metabolites and psychopathology. Significant positive correlation was found between 5-HIAA with VMA and HVA. Conclusion: The present study indicates that noninvasive measurement of monoamine metabolites in urine may be of value in differentiating patients with schizophrenia from controls.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume8
Issue number5
Publication statusPublished - 01-01-2015

Fingerprint

Vanilmandelic Acid
Antipsychotic Agents
Schizophrenia
Homovanillic Acid
Psychopathology
Neurotransmitter Agents
Therapeutics
Urine
Diagnostic and Statistical Manual of Mental Disorders
Dopamine
Serotonin
Norepinephrine
High Pressure Liquid Chromatography
Pathology
indoleacetic acid
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{38c1ed6957ad4cfabf85ced611340859,
title = "Changes in urinary monoamine metabolites with antipsychotic treatment in schizophrenia",
abstract = "Objective: Monoamine neurotransmitters have been considered important mediators of schizophrenia pathology and antipsychotic drug action. This study examines the level of monoamine metabolites, homovanillic acid (HVA), 5-hydroxy indole acetic acid (5-HIAA), and vanillylmandelic acid (VMA), monoamine metabolites of major neurotransmitters dopamine, serotonin and norepinephrine, respectively in urine of patients with schizophrenia as compared to normal controls and the change in monoamine metabolites with antipsychotic treatment. Methods: Thirty-four drug-free patients with schizophrenia diagnosed with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria and 15 normal controls were taken for the study. Patients were assessed for psychopathology using positive and negative syndrome scale (PANSS) scale at baseline and 4 weeks after the treatment. Urinary monoamine metabolites (HVA, 5-HIAA, and VMA) were measured before and after 4 weeks of treatment using high-performance liquid chromatography. Results: There was a trend toward higher levels of HVA and VMA in the patients as compared to controls. There was a trend toward reduction in 5-HIAA levels with treatment in patients with schizophrenia. No correlation was found between the levels of monoamine metabolites and psychopathology. Significant positive correlation was found between 5-HIAA with VMA and HVA. Conclusion: The present study indicates that noninvasive measurement of monoamine metabolites in urine may be of value in differentiating patients with schizophrenia from controls.",
author = "Manu Arora and Daya Ram and Praharaj, {Samir Kumar}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "111--115",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "5",

}

Changes in urinary monoamine metabolites with antipsychotic treatment in schizophrenia. / Arora, Manu; Ram, Daya; Praharaj, Samir Kumar.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, No. 5, 01.01.2015, p. 111-115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes in urinary monoamine metabolites with antipsychotic treatment in schizophrenia

AU - Arora, Manu

AU - Ram, Daya

AU - Praharaj, Samir Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: Monoamine neurotransmitters have been considered important mediators of schizophrenia pathology and antipsychotic drug action. This study examines the level of monoamine metabolites, homovanillic acid (HVA), 5-hydroxy indole acetic acid (5-HIAA), and vanillylmandelic acid (VMA), monoamine metabolites of major neurotransmitters dopamine, serotonin and norepinephrine, respectively in urine of patients with schizophrenia as compared to normal controls and the change in monoamine metabolites with antipsychotic treatment. Methods: Thirty-four drug-free patients with schizophrenia diagnosed with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria and 15 normal controls were taken for the study. Patients were assessed for psychopathology using positive and negative syndrome scale (PANSS) scale at baseline and 4 weeks after the treatment. Urinary monoamine metabolites (HVA, 5-HIAA, and VMA) were measured before and after 4 weeks of treatment using high-performance liquid chromatography. Results: There was a trend toward higher levels of HVA and VMA in the patients as compared to controls. There was a trend toward reduction in 5-HIAA levels with treatment in patients with schizophrenia. No correlation was found between the levels of monoamine metabolites and psychopathology. Significant positive correlation was found between 5-HIAA with VMA and HVA. Conclusion: The present study indicates that noninvasive measurement of monoamine metabolites in urine may be of value in differentiating patients with schizophrenia from controls.

AB - Objective: Monoamine neurotransmitters have been considered important mediators of schizophrenia pathology and antipsychotic drug action. This study examines the level of monoamine metabolites, homovanillic acid (HVA), 5-hydroxy indole acetic acid (5-HIAA), and vanillylmandelic acid (VMA), monoamine metabolites of major neurotransmitters dopamine, serotonin and norepinephrine, respectively in urine of patients with schizophrenia as compared to normal controls and the change in monoamine metabolites with antipsychotic treatment. Methods: Thirty-four drug-free patients with schizophrenia diagnosed with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria and 15 normal controls were taken for the study. Patients were assessed for psychopathology using positive and negative syndrome scale (PANSS) scale at baseline and 4 weeks after the treatment. Urinary monoamine metabolites (HVA, 5-HIAA, and VMA) were measured before and after 4 weeks of treatment using high-performance liquid chromatography. Results: There was a trend toward higher levels of HVA and VMA in the patients as compared to controls. There was a trend toward reduction in 5-HIAA levels with treatment in patients with schizophrenia. No correlation was found between the levels of monoamine metabolites and psychopathology. Significant positive correlation was found between 5-HIAA with VMA and HVA. Conclusion: The present study indicates that noninvasive measurement of monoamine metabolites in urine may be of value in differentiating patients with schizophrenia from controls.

UR - http://www.scopus.com/inward/record.url?scp=84940932988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940932988&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84940932988

VL - 8

SP - 111

EP - 115

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 5

ER -